Dr. Stan Louie is a Professor of Clinical Pharmacy at the University of Southern California (USC) School of Pharmacy, affiliated with the Ginsburg Institute of Biomedical Therapeutics. His research focuses on translational pharmacology, leveraging metabolomics and lipidomics to identify drug targets for neurodegenerative diseases, inflammation, and regenerative therapies. Dr. Louie has advanced four therapeutic modalities from preclinical stages to clinical evaluation, with a particular emphasis on Alzheimer’s disease, retinal degeneration, and traumatic brain injury (TBI). His academic training and career are rooted in clinical pharmacy, with a strong emphasis on drug discovery and development. Key research interests include the role of bioactive lipids in neuroinflammation, the impact of APOE4 genotype on brain metabolism, and the development of targeted therapies using antibody-drug conjugates and nanoparticle systems. Dr. Louie’s recent work highlights innovations such as transcorneal electrical stimulation for retinal neuroprotection, hydroxypropyl-β-cyclodextrin barriers for antiviral delivery, and omega-3 fatty acid supplementation in TBI patients. His lab also explores the mechanistic links between lipid metabolism, inflammation, and disease progression in conditions like alcoholic hepatitis and liver cancer. His awards include Fellowships from the American and California Societies of Health System Pharmacists (2000 and 1998, respectively), the Rho Chi Honor Society (1985), and a March of Dimes Research Fellowship (1979–1982). His research has been published in high-impact journals such as *Nature Communications*, *ACS Chemical Neuroscience*, and *Molecular Cancer Therapeutics*. Dr. Louie’s translational efforts bridge basic science and clinical application, with a focus on preclinical and early-phase clinical trials. His lab collaborates on projects involving drug delivery systems, biomarker discovery, and the optimization of therapeutic strategies for chronic and acute conditions.






